Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, attributed to the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Company Developments - The company reported a stock price increase of over 10%, with a current price of 3.4 HKD and a trading volume of 11.32 million HKD [1] - TONO-i will be a key part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - The device provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, enhancing patient compliance with glaucoma medication [1] Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which has since been expanded to include Thailand and Malaysia, effective from August 2024 [1]
兆科眼科-B再涨超10% 公司向国家药监局取得供测量眼压的TONO-i的医疗器械注册证